Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4981902 | 0.89 | — | — | |
| SCHEMBL3922056 | 0.76 | PDE4A (0.32) | USP2SLCO1B1 | |
| SCHEMBL313770 | 0.76 | PDE4A (0.32) | USP2SLCO1B1 | |
| SCHEMBL315273 | 0.76 | PDE4A (0.32) | USP2SLCO1B1 | |
| Hydrochloric Acid SCHEMBL5866744 | 0.74 | PDE4A (0.31) | — | |
| SCHEMBL313626 | 0.71 | — | — | |
| SCHEMBL455830 | 0.68 | USP2 (0.39) | USP2SLCO1B1 | |
| SCHEMBL7944202 | 0.66 | PDE4A (0.31) | — | |
| SCHEMBL1134674 | 0.63 | USP2 (0.46) | USP2SLCO1B1 | |
| SCHEMBL4268666 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080241903-A1 | In vivo site-sepecific incorporation of N-acetyl-galactosamine amino acids in eubacteria | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-10-02 | — | — | US | claimed |
| US-20080064059-A1 | In Vivo Site-Specific Incorporation of N-Acetyl-Galactosamine Amino Acids in Eubacteria | SCRIPPS RESEARCH INSTITUTE | 2008-03-13 | — | — | US | claimed |
| US-20060110796-A1 | In vivo site-specific incorporation of N-acetyl-galactosamine amino acids in eubacteria | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-05-25 | — | — | US | claimed |
| US-20080241903-A1 | In vivo site-sepecific incorporation of N-acetyl-galactosamine amino acids in eubacteria | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-10-02 | — | — | US | disclosed |
| US-7378263-B2 | In vivo site-specific incorporation of N-acetyl-galactosamine amino acids in eubacteria | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-05-27 | — | — | US | disclosed |
| US-20080064059-A1 | In Vivo Site-Specific Incorporation of N-Acetyl-Galactosamine Amino Acids in Eubacteria | SCRIPPS RESEARCH INSTITUTE | 2008-03-13 | — | — | US | disclosed |
| US-20060110796-A1 | In vivo site-specific incorporation of N-acetyl-galactosamine amino acids in eubacteria | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060110796-A1 | In vivo site-specific incorporation of N-acetyl-galactosamine amino acids in eubacteria | FUT5, GALNT14, GALNT6 | USP2 1437/4885SLCO1B1 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.